My research expertise is computational chemical genomics (molecular modeling, molecular screenings, and molecular simulations). I apply my expertise with molecular biology for the design and development of biologically active small molecules targeting early markers of lethal cancer disease, for precision therapy and prevention.
Learn more about the current cancer research projects in the lab.
In 2007 in the journal PNAS first reported IN SILICO DRUG REPURPOSING approach for the identification of non steroidal Androgen Receptor antagonists.
In December 2012, the journal Current Topics in Medicinal Chemistry dedicates a SPECIAL EDITION edited by Dr. Bisson entitled ''Computational Chemogenomics in Drug Design and Discovery''.
In July 2015, special issue on ''Assessing the Carcinogenic Potential of Chemical Mixtures in the Environment'' in Carcinogenesis. Dr. Bisson served as a co-author in all twelve publications and as co-corresponding author in three reviews.
In July 2015, Dr. Bisson's leadership work on the Halifax project is highlighted by AAAS Science News in EurekAlert.
In December 2015, the first study reporting Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction is published in Nature Commun. by Dr. Bisson and collaborators.
In February 2017, Dr. Bisson's lead work "Low-Dose Mixture Hypothesis of Carcinogenesis: Scientific Underpinnings and Research Recommendations" is published in the journal Environmental Health Perspectives (EHP) of the NIEHS.
March 2018: Dr. Bisson and collaborators uncovered a potential drug target for stopping castration-resistant prostate tumors. The work was published in the journal PNAS.
In November 2018, Dr Bisson and colleagues showed that an Anti-diabetes drug impact on gut bacteria may offer clues to treating some metabolic diseases. The work is published in Nature Medicine.